The light and dark side of bisphosphonates

Eijiro Jimi; Masamichi Takami; Toru Hiraga; Ichiro Nakamura; Masahiro Urade; Yoichi Miyamoto

doi:10.2330/joralbiosci.51.177

The light and dark side of bisphosphonates

Eijiro Jimi, Masamichi Takami, Toru Hiraga, Ichiro Nakamura, Masahiro Urade, Yoichi Miyamoto

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.

Original language	English
Pages (from-to)	177-187
Number of pages	11
Journal	journal of oral biosciences
Volume	51
Issue number	4
DOIs	https://doi.org/10.2330/joralbiosci.51.177
Publication status	Published - Nov 2009
Externally published	Yes

All Science Journal Classification (ASJC) codes

Medicine (miscellaneous)
Biochemistry, Genetics and Molecular Biology(all)
Dentistry(all)

Access to Document

10.2330/joralbiosci.51.177

Fingerprint Dive into the research topics of 'The light and dark side of bisphosphonates'. Together they form a unique fingerprint.

Cite this

@article{50ac8fefb758466fb33837e627031815,

title = "The light and dark side of bisphosphonates",

abstract = "Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,{"}the light and dark side{"}so to speak, to facilitate a full understanding of these compounds.",

author = "Eijiro Jimi and Masamichi Takami and Toru Hiraga and Ichiro Nakamura and Masahiro Urade and Yoichi Miyamoto",

year = "2009",

month = nov,

doi = "10.2330/joralbiosci.51.177",

language = "English",

volume = "51",

pages = "177--187",

journal = "Journal of Oral Biosciences",

issn = "1349-0079",

publisher = "Japanese Association for Oral Biology",

number = "4",

}

TY - JOUR

T1 - The light and dark side of bisphosphonates

AU - Jimi, Eijiro

AU - Takami, Masamichi

AU - Hiraga, Toru

AU - Nakamura, Ichiro

AU - Urade, Masahiro

AU - Miyamoto, Yoichi

PY - 2009/11

Y1 - 2009/11

N2 - Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.

AB - Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.

UR - http://www.scopus.com/inward/record.url?scp=74549127194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549127194&partnerID=8YFLogxK

U2 - 10.2330/joralbiosci.51.177

DO - 10.2330/joralbiosci.51.177

M3 - Review article

AN - SCOPUS:74549127194

VL - 51

SP - 177

EP - 187

JO - Journal of Oral Biosciences

JF - Journal of Oral Biosciences

SN - 1349-0079

IS - 4

ER -